Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program

This study has been completed.
Sponsor:
Collaborator:
Canadian Arthritis Network
Information provided by (Responsible Party):
Dr. Mary Bell, Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier:
NCT01054131
First received: January 21, 2010
Last updated: December 23, 2011
Last verified: December 2011

January 21, 2010
December 23, 2011
January 2010
September 2011   (final data collection date for primary outcome measure)
DMARD adherence [ Time Frame: 0, 3, 6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01054131 on ClinicalTrials.gov Archive Site
  • coping efficacy [ Time Frame: 0, 3 6 months ] [ Designated as safety issue: No ]
  • self-management [ Time Frame: 0, 3, 6 months ] [ Designated as safety issue: No ]
  • anxiety [ Time Frame: 0, 3, 6 months ] [ Designated as safety issue: No ]
  • self efficacy [ Time Frame: 0, 3, 6 months ] [ Designated as safety issue: No ]
  • social support [ Time Frame: 0, 3, 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program
Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program

Inflammatory arthritis (IA) is a major cause of long-term disability. Peer support may be a solution to the common problem of delayed treatment. Early peer support may result in improved use of therapy, higher self-efficacy, reduced anxiety, and improved coping in the first two years post-diagnosis. The whole intervention study comprises of two parts: The first part involves the development and testing of a peer mentor training initiative, which is called "Peer to Peer Mentoring: Facilitating Individuals with Early Inflammatory Arthritis to Manage their Arthritis - Peer Mentor Training". The second part, which is the focus of this study, involves the delivery of a one-on-one peer support intervention from a trained peer mentor to an individual newly diagnosed with EIA. The feasibility and acceptability of the program will be determined, as well as the health outcomes following the participation of the program.

Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Primary Purpose: Supportive Care
  • Early Inflammatory Arthritis
  • Chronic Disease
Behavioral: peer support
A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
December 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Have EIA disease duration within 6-52 weeks
  2. At least 3 swollen joints, assessed by the treating rheumatologist, OR positive compression test for the metacarpophalangeal joints OR positive compression test for the metatarsophalangeal joints OR at least 30 minutes of morning stiffness
  3. Prescription of a DMARD/biologic by the treating rheumatologist
  4. Ability to speak and understand English without the aid of a secondary support person; AND
  5. Capability to provide informed consent.

Exclusion Criteria:

  1. IA disease duration less than 6 weeks or greater than 1 year
  2. Previous or ongoing DMARD or biologic treatment
  3. Inability to speak or read grade 6 English; AND
  4. Inability to provide informed consent
Both
Not Provided
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01054131
420-2009
No
Dr. Mary Bell, Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre
Canadian Arthritis Network
Principal Investigator: Mary J Bell, MD, FRCPC Rheumatologist, Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP